These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 22172104

  • 1. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O, Bahar A, Seker UO, Akgun E, Ozkan A, Kilic T, Tamerler C, Baysal K.
    Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
    [Abstract] [Full Text] [Related]

  • 2. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood.
    Böldicke T, Tesar M, Griesel C, Rohde M, Gröne HJ, Waltenberger J, Kollet O, Lapidot T, Yayon A, Weich H.
    Stem Cells; 2001; 19(1):24-36. PubMed ID: 11209088
    [Abstract] [Full Text] [Related]

  • 3. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.
    Zhang J, Li H, Wang X, Qi H, Miao X, Zhang T, Chen G, Wang M.
    Biotechnol Prog; 2012 Jul; 28(4):981-9. PubMed ID: 22581629
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L.
    Cancer Res; 1998 Aug 01; 58(15):3209-14. PubMed ID: 9699643
    [Abstract] [Full Text] [Related]

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 01; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 6. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
    Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, Saenz P, Martínez A, Casal JI.
    Clin Cancer Res; 2005 Sep 01; 11(17):6280-90. PubMed ID: 16144932
    [Abstract] [Full Text] [Related]

  • 7. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H, Rajabibazl M, Ebrahimizadeh W, Dehbidi GR.
    Microvasc Res; 2015 Jan 01; 97():13-8. PubMed ID: 25250517
    [Abstract] [Full Text] [Related]

  • 8. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
    Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S.
    Mol Immunol; 2012 Feb 01; 50(1-2):35-41. PubMed ID: 22208996
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.
    Leukemia; 2003 Mar 01; 17(3):604-11. PubMed ID: 12646950
    [Abstract] [Full Text] [Related]

  • 10. ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.
    Ballmer-Hofer K, A C Hyde C, Schleier T, Avramovic D.
    Int J Mol Sci; 2018 May 01; 19(5):. PubMed ID: 29723982
    [Abstract] [Full Text] [Related]

  • 11. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R, Xiong DS, Shao XF, Liu J, Xu YF, Xu YS, Liu HZ, Zhu ZP, Yang CZ.
    Acta Pharmacol Sin; 2004 Oct 01; 25(10):1292-8. PubMed ID: 15456530
    [Abstract] [Full Text] [Related]

  • 12. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 01; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 13. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG, Kim TD, Li G, Yoon WH, Chae CB.
    Clin Cancer Res; 2005 Apr 01; 11(7):2651-61. PubMed ID: 15814646
    [Abstract] [Full Text] [Related]

  • 14. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS, Pyun BJ, Kim SW, Shim SR, Nam JR, Yoo JY, Jin Y, Jin J, Kwon YG, Yun CO, Nam DH, Oh K, Lee DS, Lee SH, Yoo JS.
    MAbs; 2015 Apr 01; 7(5):957-68. PubMed ID: 25942475
    [Abstract] [Full Text] [Related]

  • 15. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.
    Eur J Cancer; 2011 Oct 01; 47(15):2353-63. PubMed ID: 21680174
    [Abstract] [Full Text] [Related]

  • 16. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K.
    EMBO J; 1996 Jan 15; 15(2):290-98. PubMed ID: 8617204
    [Abstract] [Full Text] [Related]

  • 17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.
    Life Sci; 2006 Nov 17; 79(25):2370-81. PubMed ID: 16959272
    [Abstract] [Full Text] [Related]

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G.
    Exp Hematol; 2004 Jun 15; 32(6):526-35. PubMed ID: 15183893
    [Abstract] [Full Text] [Related]

  • 20. Cat's whiskers tea (Orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation.
    Ahamed MB, Aisha AF, Nassar ZD, Siddiqui JM, Ismail Z, Omari SM, Parish CR, Majid AM.
    Nutr Cancer; 2012 Jun 15; 64(1):89-99. PubMed ID: 22136553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.